RMC No. 125-2022 updates the FDA VAT-exempt medicines list, deleting certain COVID-19 treatment medicines under the CREATE Act.

Businesses selling, purchasing, importing, distributing, prescribing, or accounting for medicines used in COVID-19 treatment must immediately re-check the current FDA-published List of VAT-Exempt Medicines before treating those medicines as VAT-exempt. RMC No. 125-2022 makes a critical update under Republic Act No. 11534, or the CREATE Act: the FDA endorsed updates to the List of VAT-Exempt Medicines that delete certain medicines prescribed for COVID-19 treatment. For finance teams, pharmacy operators, hospitals, clinics, importers, distributors, and corporate buyers, the practical consequence is straightforward: once a medicine is removed from the FDA-published VAT-exempt list, it should no longer be handled as a CREATE Act VAT-exempt medicine merely because it was previously associated with COVID-19 treatment.

What Changed Under RMC No. 125-2022

RMC No. 125-2022, issued on September 6, 2022, publishes the August 17, 2022 letter from FDA Director General Samuel A. Zacate endorsing updates to the List of VAT-Exempt Medicines under the CREATE Act. The update is significant because it deletes certain medicines prescribed for COVID-19 treatment from the list of medicines covered by the VAT exemption.

The key change is not the creation of a new filing form, a new tax rate, or a new documentary submission. The key change is the correction of the list that taxpayers must use when determining whether a medicine is VAT-exempt under the CREATE Act. For businesses, this is a pricing, invoicing, purchasing, and tax compliance issue. The treatment of a product as VAT-exempt depends on whether it is covered by the updated FDA-published list, not merely on whether the medicine was historically used, prescribed, or marketed in connection with COVID-19 treatment.

This is especially relevant to taxpayers searching for BIR VAT-exempt medicines, CREATE Act VAT exemption medicines, COVID-19 treatment medicines VAT, FDA List of VAT-Exempt Medicines, and RMC 125-2022 VAT exemption. The search issue is practical: accounting teams need to know whether a particular medicine may still be sold or purchased without VAT under the CREATE Act framework.

Who Is Affected

The most affected taxpayers are businesses and institutions that handle medicines in their ordinary operations. This includes pharmaceutical companies, drugstores, hospitals, clinics, healthcare providers, medical procurement offices, medicine importers, wholesalers, distributors, and corporate taxpayers purchasing covered medicines for employee health programs or medical operations.

CFOs, corporate accountants, tax managers, and in-house counsel should also pay attention because the risk is not limited to sellers. Purchasers may rely on invoices and supplier classifications when recording input tax, VAT-exempt purchases, costs, or reimbursements. If the supplier continues to classify a medicine as VAT-exempt after it has been deleted from the FDA-published list, the transaction may be incorrectly documented from a tax compliance perspective.

For businesses with inventory systems, product masters, point-of-sale tax codes, ERP tax settings, and procurement catalogues, the update requires more than legal awareness. It requires operational correction. A medicine that is no longer on the VAT-exempt list should not remain coded as VAT-exempt in billing, purchasing, inventory, or accounting systems solely because it was previously included or because it relates to COVID-19 treatment.

Effective Date and Compliance Rule

RMC No. 125-2022 expressly refers to the rule clarified in Q&A No. 1 of RMC No. 99-2021: the effectivity of the VAT exemption of covered medicines and medical devices under the CREATE Act takes effect on the date of publication by the FDA of updates to the list. This rule matters because it ties VAT exemption to the FDA publication of the updated list, not to a taxpayer’s internal review date, supplier notification date, or later accounting cut-off.

The document identifies two important dates. The FDA endorsement letter is dated August 17, 2022. RMC No. 125-2022 was issued on September 6, 2022. Businesses should therefore review transactions around the FDA publication of the relevant update and confirm whether any medicine deleted from the list was still treated as VAT-exempt after the applicable FDA publication date.

The compliance rule is specific: determine coverage by reference to the FDA-published List of VAT-Exempt Medicines as updated. The document does not provide a separate grace period, transition rule, or extended deadline for businesses that have not updated their accounting systems. It also does not identify a separate application process for taxpayers to continue treating deleted medicines as VAT-exempt under this specific issuance.

Key Compliance Requirements for Businesses

Businesses should first identify all medicines in their product, purchase, and sales records that were treated as VAT-exempt because they were prescribed for COVID-19 treatment. Those items should be compared against the updated FDA-published List of VAT-Exempt Medicines referenced by RMC No. 125-2022.

Second, businesses should update tax codes in their accounting, invoicing, POS, ERP, procurement, and inventory systems. The VAT classification used in invoices and receipts should match the status of the medicine under the FDA-published list. This is particularly important for businesses with large inventories or multiple branches, because a central master-data error can create repeated VAT classification mistakes across many transactions.

Third, businesses should review supplier invoices and customer billings issued after the relevant FDA publication date. The finance team should check whether deleted medicines were still invoiced as VAT-exempt. Where necessary, management should consult tax counsel on whether corrective documentation, accounting adjustments, or internal controls are required.

Fourth, in-house counsel and compliance officers should preserve copies of the relevant FDA-published list, the RMC, and internal tax classification approvals. In a BIR audit, the business should be able to show why a medicine was treated as VAT-exempt or taxable for a specific transaction date.

Penalties and Audit Risk for Non-Compliance

RMC No. 125-2022 does not state a special penalty unique to this update. However, the practical BIR audit risk is that a taxpayer may incorrectly treat a medicine as VAT-exempt after it has been deleted from the FDA-published List of VAT-Exempt Medicines. That error may affect sales documentation, VAT reporting, purchase records, and tax accounting positions.

The risk is highest where the business relies on outdated product classifications, old supplier memoranda, or blanket assumptions that all COVID-19-related medicines remain VAT-exempt. RMC No. 125-2022 confirms that updates to the FDA list matter, and that effectivity follows FDA publication of the updates. Tax teams should therefore avoid static tax coding for medicines covered by the CREATE Act VAT exemption and should instead maintain a review process whenever the FDA list is updated.

Practical Steps Businesses Should Take Now

Businesses should immediately conduct a product-level VAT review of medicines previously classified as CREATE Act VAT-exempt COVID-19 treatment medicines. The review should be done by SKU, generic name, brand name, supplier, and transaction period where those details are available in the taxpayer’s records.

Management should then assign responsibility between tax, accounting, procurement, operations, and IT. Tax should determine the correct VAT classification. Accounting should review invoices and returns. Procurement should coordinate with suppliers. IT should update tax codes in systems. Operations should make sure branches, pharmacies, billing desks, and sales teams apply the updated classification consistently.

For CFOs and corporate accountants, the immediate question is not simply whether a medicine is related to COVID-19. The correct question is whether that medicine remains in the FDA-published List of VAT-Exempt Medicines as updated under the CREATE Act. That distinction is the core compliance message of RMC No. 125-2022.

How Ablola, Saribong & Gueco Can Help

Ablola, Saribong & Gueco advises businesses on BIR compliance, VAT classification, tax audit readiness, healthcare and pharmaceutical tax issues, and CREATE Act-related tax concerns. For companies that sell, distribute, import, procure, or account for medicines, we can assist in reviewing VAT treatment, updating compliance protocols, preparing audit documentation, and coordinating tax-sensitive operational changes.

If your business needs assistance reviewing the impact of RMC No. 125-2022 on VAT-exempt medicines, COVID-19 treatment medicine classifications, supplier invoices, or BIR audit exposure, contact Ablola, Saribong & Gueco through MakatiLawFirm.com.


Leave a Comment

Your email address will not be published. Required fields are marked *